Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05002270 · ClinicalTrials.gov registry record · Phase 1

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

A Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Jacobio Pharmaceuticals Co..

Completed
Registry status
Phase 1
Development phase
29
Enrollment target
4
Study locations

NCT05002270 is a Phase 1 study of Advanced Solid Tumor and NSCLC that has completed, run by Jacobio Pharmaceuticals Co.. The registered enrollment target is 29 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05002270, a Phase 1 study of Advanced Solid Tumor and NSCLC, has completed, sponsored by Jacobio Pharmaceuticals Co..

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target
4
Study locations

Study Summary

This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

Conditions Studied

Advanced Solid Tumor NSCLC CRC

Interventions

  • DRUG JAB-21822 (KRAS G12C inhibitor)
  • DRUG Cetuximab (EGFR inhibitor)

Study Locations (4)

Arizona

  • Mayo Clinc - Phoenix
  • Mayo Clinc - Scottsdale

Florida

  • Mayo Clinc - Jacksonville

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2021-09-03
Est. Completion 2025-02-12
Phase Phase 1

Sponsor

Jacobio Pharmaceuticals Co.

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05002270

The ClinicalTrials.gov registry entry for NCT05002270 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (85% lower). The listed sponsor is Jacobio Pharmaceuticals Co., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which JAB-21822 (KRAS G12C inhibitor) is the first listed.

NCT05002270 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Utah.

Frequently Asked Questions

What is clinical trial NCT05002270 about?

NCT05002270 is a clinical study titled "JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation". This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

What is the current status of trial NCT05002270?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2021-09-03. Estimated completion is 2025-02-12.

What conditions does trial NCT05002270 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, NSCLC, CRC.

What interventions are being tested in trial NCT05002270?

The interventions under investigation include: JAB-21822 (KRAS G12C inhibitor) (DRUG), Cetuximab (EGFR inhibitor) (DRUG).

Who is sponsoring clinical trial NCT05002270?

This trial is sponsored by Jacobio Pharmaceuticals Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05002270 being conducted?

This trial has 4 study locations across Arizona, Florida, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

NSCLC

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.